The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / FDA Approves Tocilizumab to Treat Systemic Sclerosis-Associated ILD

FDA Approves Tocilizumab to Treat Systemic Sclerosis-Associated ILD

March 25, 2021 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Systemic sclerosis, also known as scleroderma, is an autoimmune disease associated with fibrosis of the skin and other organs. Interstitial lung disease (ILD) can occur in 25–90% of systemic sclerosis patients, causing inflammation and lung scarring that can be life threatening.1 Systemic sclerosis, which has no cure and may worsen over time. Mortality from all pulmonary complications in patients with scleroderma is estimated to be up to 33%. The incidence of scleroderma in the U.S. is approximately 20 cases per 1 million population.2

You Might Also Like
  • Evaluation & Treatment of Systemic Sclerosis-ILD in the New Decade
  • FDA Approves Nintedanib for SSc-ILD, But Temper Your Expectations
  • FDA Approves Subcutaneous Tocilizumab for Ages 2–17
Also By This Author
  • Abaloparatide-SC May Reduce Fractures for Osteoporosis & New FDA Safety Website

On March 4, the U.S. Food and Drug Administration (FDA) approved subcutaneous and intravenous tocilizumab (Actemra) to slow the rate of declining pulmonary function in adults with systemic sclerosis-associated ILD.3–5 Previously, the FDA granted tocilizumab priority review designation for this condition, because systemic sclerosis-associated ILD is an incapacitating condition with inadequate treatment options.6 Tocilizumab is the first biologic therapy approved by the FDA to treat this disease.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Background
This FDA approval is based on data from the focuSSced clinical trial, a phase 3 randomized, double-blind, placebo-controlled study of adults (N=212) with systemic sclerosis.7 Supportive information from the phase 2/3, randomized, double-blind, placebo-controlled faSScinate study was also used for the approval.8

The focuSSced study did not meet its primary endpoint, which was the change from baseline to week 48 in the modified Rodnan Skin Score, a standard outcome measure for skin fibrosis in systemic sclerosis. The study also did not demonstrate a statistically significant effect on the modified Rodnan Skin Score.7 However, the patients who received tocilizumab maintained their baseline level of lung function as measured by the forced vital capacity (FVC), without further declination of lung capacity. The FVC is a common measure of lung function that assesses how much air can be exhaled, and the percent predicted FVC. The predicted FVC compares the study subject’s FVC to that expected for a healthy person of the same age, gender, race and height. In the faSScinate study, tocilizumab did not show significant skin thickening and fewer patients who received tocilizumab than patients that received placebo had a decline in their FVC of more than 10%.8

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In patients with systemic sclerosis-associated ILD in the focuSSced study, tocilizumab-treated patients had a smaller decline in mean percent predicted FVC than placebo-treated patients (0.07% vs. -6.4%, mean difference 6.47%) and a smaller decline in FVC than placebo-treated patients (mean change -14 mL vs. -255 mL; mean difference 241 mL). The mean change from baseline to week 48 in the modified Rodnan Skin Score in tocilizumab-treated patients compared with placebo-treated patients was -5.88 vs. -3.77 (mean difference: -2.11).7

Pages: 1 2 | Single Page

Filed Under: Drug Updates Tagged With: FDA, FDA approval, ILD, interstitial lung disease (ILD), systemic sclerosis (SSc), systemic sclerosis-associated ILD, tocilizumab, U.S. Food and Drug Administration (FDA)

You Might Also Like:
  • Evaluation & Treatment of Systemic Sclerosis-ILD in the New Decade
  • FDA Approves Nintedanib for SSc-ILD, But Temper Your Expectations
  • FDA Approves Subcutaneous Tocilizumab for Ages 2–17
  • Alendronate May Provide Cardiovascular Benefits; Plus FDA Approves Subcutaneous Tocilizumab

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)